Connection

Co-Authors

This is a "connection" page, showing publications co-authored by FREDRICK B HAGEMEISTER and L JEFFREY MEDEIROS.
Connection Strength

0.950
  1. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(?) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. Br J Haematol. 2013 Sep; 162(5):631-8.
    View in: PubMed
    Score: 0.118
  2. Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin lymphoma. Am J Surg Pathol. 2004 Apr; 28(4):489-95.
    View in: PubMed
    Score: 0.062
  3. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer. 2003 Jul 15; 98(2):310-4.
    View in: PubMed
    Score: 0.059
  4. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol. 2002 Feb; 13(2):318-22.
    View in: PubMed
    Score: 0.054
  5. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. J Clin Oncol. 2022 01 10; 40(2):202-212.
    View in: PubMed
    Score: 0.053
  6. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):639-646.
    View in: PubMed
    Score: 0.042
  7. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One. 2018; 13(3):e0191461.
    View in: PubMed
    Score: 0.041
  8. Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2017 07 27; 130(4):472-477.
    View in: PubMed
    Score: 0.039
  9. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017 12; 58(12):2833-2844.
    View in: PubMed
    Score: 0.039
  10. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol. 2017 03; 176(5):750-758.
    View in: PubMed
    Score: 0.038
  11. Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma. Br J Haematol. 2017 11; 179(3):503-506.
    View in: PubMed
    Score: 0.036
  12. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk. 2016 Mar; 16(3):122-8.
    View in: PubMed
    Score: 0.035
  13. Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma. Br J Haematol. 2015 Nov; 171(4):509-16.
    View in: PubMed
    Score: 0.034
  14. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015 May 01; 92(1):113-21.
    View in: PubMed
    Score: 0.034
  15. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014 Sep; 166(6):891-901.
    View in: PubMed
    Score: 0.032
  16. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):384-91.
    View in: PubMed
    Score: 0.031
  17. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma. 2013 Dec; 54(12):2631-8.
    View in: PubMed
    Score: 0.029
  18. Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases? Curr Hematol Malig Rep. 2011 Mar; 6(1):58-66.
    View in: PubMed
    Score: 0.025
  19. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.
    View in: PubMed
    Score: 0.022
  20. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.021
  21. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005 Oct 01; 23(28):7013-23.
    View in: PubMed
    Score: 0.017
  22. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003 Feb 01; 97(3):586-91.
    View in: PubMed
    Score: 0.014
  23. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Williston Park). 2002 Aug; 16(8 Suppl 7):27-31.
    View in: PubMed
    Score: 0.014
  24. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clin Lymphoma. 2001 Jun; 2(1):40-6.
    View in: PubMed
    Score: 0.013
  25. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma. 2001 May; 41(5-6):535-44.
    View in: PubMed
    Score: 0.013
  26. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage I: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. J Clin Oncol. 2001 Jan 15; 19(2):398-405.
    View in: PubMed
    Score: 0.012
  27. Infusional vinorelbine in relapsed or refractory lymphomas. Leuk Lymphoma. 2000 Oct; 39(3-4):291-9.
    View in: PubMed
    Score: 0.012
  28. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000 Jan; 11(1):69-72.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.